Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27059386 | 0.87 | CHRM2 (0.44) | SETD7MAP4K4GPR119HDAC1CHRM2 | |
| SCHEMBL25949561 | 0.87 | CHRM2 (0.44) | SETD7MAP4K4GPR119HDAC1CHRM2 | |
| SCHEMBL12450345 | 0.84 | PSEN1 (0.40) | SETD7MAP4K4GPR119CHRM2CHRM1 | |
| SCHEMBL30419362 | 0.83 | PARP1 (0.40) | SETD7MAP4K4GPR119CHRM2CHRM1 | |
| SCHEMBL31084572 | 0.83 | PARP1 (0.40) | SETD7MAP4K4GPR119CHRM2CHRM1 | |
| SCHEMBL26427730 | 0.83 | PARP1 (0.40) | SETD7MAP4K4GPR119CHRM2CHRM1 | |
| SCHEMBL26427727 | 0.83 | PARP1 (0.40) | SETD7MAP4K4GPR119CHRM2CHRM1 | |
| SCHEMBL17631439 | 0.83 | USP2 (0.40) | SETD7MAP4K4GPR119HDAC1CHRM2 | |
| SCHEMBL17631441 | 0.83 | USP2 (0.40) | SETD7MAP4K4GPR119HDAC1CHRM2 | |
| SCHEMBL38653317 | 0.81 | NR1H3 (0.39) | CHRM2CHRM1CHRM3HSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | SETD7 4162/4885MAP4K4 2295/4885GPR119 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.